Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PsomagenXKRX:950200 -1.22%72 Return-on-Tangible-Equity is 45.45% as of Jun. 2026. GuruFocus rates XKRX:950200 with a GF Score™ of 72/100 and a GF Value™ of ₩5,268.78 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 186 Medical Diagnostics & Research companies, Psomagen ranks better than 62.9% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Psomagen's annualized net income for the quarter that ended in Jun. 2026 was ₩11,062 Mil. Psomagen's average shareholder tangible equity for the quarter that ended in Jun. 2026 was ₩24,338 Mil. Therefore, Psomagen's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was 45.45%.
The historical rank and industry rank for Psomagen's Return-on-Tangible-Equity or its related term are showing as below:
XKRX:950200'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -2264.46 Med: -20.45 Max: 9.57
Current: 9.57
During the past 8 years, Psomagen's highest Return-on-Tangible-Equity was 9.57%. The lowest was -2,264.46%. And the median was -20.45%.
XKRX:950200's Return-on-Tangible-Equity is ranked better than 62.9% of 186
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.765
vs XKRX:950200: 9.57
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Psomagen Return-on-Tangible-Equity Related Terms
Psomagen Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Psomagen's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKRX:950200 vs TMO, DHR, NTRA: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, Psomagen's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Psomagen Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Psomagen's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Psomagen's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 45.45% mean?
Psomagen (XKRX:950200) has a Return-on-Tangible-Equity of 45.45% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Psomagen and its competitors. According to the industry distribution chart, Psomagen ranks #69 out of 186 companies in the Medical Diagnostics & Research industry, placing it in the top 37.1%.
Is Psomagen's Return-on-Tangible-Equity too high?
Psomagen's current Return-on-Tangible-Equity is 45.45%. The Medical Diagnostics & Research industry median Return-on-Tangible-Equity is 1.77. Psomagen's value of 45.45% is 2475.1% above this industry median. Based on the distribution chart, Psomagen ranks #69 out of 186 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Psomagen has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Psomagen's Return-on-Tangible-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Psomagen ranks #69 out of 186 companies for Return-on-Tangible-Equity. This puts Psomagen in the upper half of its industry. The industry median Return-on-Tangible-Equity is 1.77. Psomagen's value of 45.45% is 2475.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
The median Return-on-Tangible-Equity among Medical Diagnostics & Research companies is 1.77, based on 186 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Psomagen's current Return-on-Tangible-Equity of 45.45% is 2475.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Psomagen and its competitors. For the Medical Diagnostics & Research industry, the median Return-on-Tangible-Equity is 1.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Psomagen's current Return-on-Tangible-Equity is 45.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Psomagen stock overvalued right now?
Based on GuruFocus' analysis, Psomagen (XKRX:950200) is currently considered Significantly Undervalued. The stock's GF Value™ is ₩5,268.78, compared to a current price of ₩3,230.00 — trading 38.7% below its estimated fair value. The current Return-on-Tangible-Equity is 45.45% and 2475.1% above the Medical Diagnostics & Research industry median of 1.77. Psomagen's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Psomagen (XKRX:950200), the current Return-on-Tangible-Equity is 45.45% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Psomagen (XKRX:950200) Overvalued in 2026?
Based on GuruFocus' analysis, Psomagen stock appears to be undervalued.
The current stock price of ₩3,230.00 is trading 38.7% below its estimated GF Value™ of ₩5,268.78.
GuruFocus considers Psomagen to be Significantly Undervalued.
Key valuation signals for XKRX:950200:
Return-on-Tangible-Equity: 45.45%
GF Value™: ₩5,268.78 vs. price of ₩3,230.00 (38.7% below fair value)
Industry Position: 2475.1% above the Medical Diagnostics & Research median (#69 of 186)
No single metric tells the full story. See the XKRX:950200 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Psomagen Inc provides total genomic solutions for both clinical and research purposes. It is mainly focused on end-to-end sequencing services. The company also offers services such as personal DNA tests, clinical sequencing, research sequencing, and others.
72GF Score
Get the complete analysis for XKRX:950200
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:950200 has been successfully added to your 
